436 related articles for article (PubMed ID: 34082161)
1. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
3. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Koreth J; Kim HT; Nikiforow S; Milford EL; Armand P; Cutler C; Glotzbecker B; Ho VT; Antin JH; Soiffer RJ; Ritz J; Alyea EP
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1516-21. PubMed ID: 24907627
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
Faraci M; Bagnasco F; Leoni M; Giardino S; Terranova P; Subissi L; Di Duca M; Di Martino D; Lanino E
Biol Blood Marrow Transplant; 2018 May; 24(5):1088-1093. PubMed ID: 29292059
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
Pichler H; Fritsch G; König M; Daxberger H; Glogova E; Pötschger U; Breuer S; Lawitschka A; Güclü ED; Karlhuber S; Holter W; Haas OA; Lion T; Matthes-Martin S
Br J Haematol; 2016 Jun; 173(6):905-17. PubMed ID: 26996395
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
9. Impact of Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Bone Transplantation on the Treatment Outcome of Non-Malignant Disease.
Choi YB; Lee JW; Sung KW; Koo HH; Kim HJ; Yoo KH
J Korean Med Sci; 2019 Feb; 34(6):e46. PubMed ID: 30787679
[TBL] [Abstract][Full Text] [Related]
10. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia.
Chen CT; Gau JP; Liu JH; Chiou TJ; Hsiao LT; Liu YC
J Chin Med Assoc; 2018 Dec; 81(12):1038-1043. PubMed ID: 30100353
[TBL] [Abstract][Full Text] [Related]
11. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
13. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
Saito B; Fukuda T; Yokoyama H; Kurosawa S; Takahashi T; Fuji S; Takahashi N; Tajima K; Kim SW; Mori SI; Tanosaki R; Takaue Y; Heike Y
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1148-1155. PubMed ID: 18804045
[TBL] [Abstract][Full Text] [Related]
14. Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Lindahl H; Vonlanthen S; Valentini D; Björklund AT; Sundin M; Mielke S; Hauzenberger D
Bone Marrow Transplant; 2022 May; 57(5):753-759. PubMed ID: 35210563
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency.
Cuvelier GD; Rubin TS; Wall DA; Schroeder ML
J Clin Immunol; 2016 Oct; 36(7):713-24. PubMed ID: 27438785
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study.
Wang L; Wang LN; Zhou JF; Gao WH; Jiang CH; Tang W; Zhao WL; Hu J; Jiang JL
Front Med (Lausanne); 2021; 8():627946. PubMed ID: 33708780
[TBL] [Abstract][Full Text] [Related]
18. Effect of Donor Lymphocyte Infusion From Two Types of Donors on Mixed Chimerism With Secondary Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation.
Ren RR; Ma LM; Xie YX; Tian WW; Wang T
Transplant Cell Ther; 2022 Mar; 28(3):152.e1-152.e7. PubMed ID: 34973501
[TBL] [Abstract][Full Text] [Related]
19. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL
Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
[TBL] [Abstract][Full Text] [Related]
20. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park SJ; Min WS; Yang IH; Kim HJ; Min CK; Eom HS; Kim DW; Han CW; Lee JW; Kim CC
Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
